Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancer

被引：0
作者：
Li, Dangran [1 ,2 ]
Weng, Shiting [1 ,3 ]
Zeng, Kai [1 ]
Xu, Hanmiao [1 ]
Wang, Wenyueyang [1 ]
Shi, Jinsong [1 ]
Chen, Jinghua [1 ]
Chen, Chen [1 ]
机构：
[1] Jiangnan Univ, Sch Life Sci & Hlth Engn, Key Lab Carbohydrate Chem & Biotechnol, Minist Educ, Wuxi 214122, Peoples R China
[2] Nanjing Univ, Coll Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210029, Peoples R China
[3] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China
来源：
GENE | 2024年 / 895卷
关键词：
LncRNA; MicroRNA; Pancreatic ductal adenocarcinoma; Chemoresistance; Targeted therapy; Tyrosine kinase; ENDOTHELIAL GROWTH-FACTOR; GEMCITABINE RESISTANCE; C-MET; FACTOR RECEPTOR; EXPRESSION; PROMOTES; OVEREXPRESSION; SURVIVAL; CHEMORESISTANCE; PROGRESSION;
D O I：
10.1016/j.gene.2023.148007
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Pancreatic cancer (PC) is one of the most malignant tumors with a dismal survival rate, this is primarily due to inevitable chemoresistance. Dysfunctional tyrosine kinases (TKs) and long non-coding RNAs (lncRNAs) affect the drug resistance and prognosis of PC. Here, we summarize the mechanisms by which TKs or lncRNAs mediate drug resistance and other malignant phenotypes. We also discuss that lncRNAs play oncogenic or tumor suppressor roles and different mechanisms including lncRNA-proteins/microRNAs to mediate drug resistance. Furthermore, we highlight that lncRNAs serve as upstream regulators of TKs mediating drug resistance. Finally, we display the clinical significance of TKs (AXL, EGFR, IGF1R, and MET), clinical trials, and lncRNAs (LINC00460, PVT1, HIF1A-AS1). In the future, TKs and lncRNAs may become diagnostic and prognostic biomarkers or drug targets to overcome the drug resistance of PC.
引用
收藏
页数：11
相关论文
共 108 条
  • [51] PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer
    Liu, Yun-Fei
    Luo, Dong
    Li, Xia
    Li, Zhi-Qiang
    Yu, Xiao
    Zhu, Hong-Wei
    [J]. PANCREAS, 2021, 50 (02) : 227 - 234
  • [52] c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer
    Lux, Alexander
    Kahlert, Christoph
    Gruetzmann, Robert
    Pilarsky, Christian
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (13):
  • [53] Liposomal Irinotecan+5-FU/LV in Metastatic Pancreatic Cancer Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
    Macarulla Mercade, Teresa
    Chen, Li-Tzong
    Li, Chung-Pin
    Siveke, Jens T.
    Cunningham, David
    Bodoky, Gyorgy
    Blanc, Jean-Frederic
    Lee, Kyung-Hun
    Dean, Andrew
    Belanger, Bruce
    Wang-Gillam, Andrea
    [J]. PANCREAS, 2020, 49 (01) : 62 - 75
  • [54] Exosome-Based Cell-Cell Communication in the Tumor Microenvironment
    Maia, Joana
    Caja, Sergio
    Strano Moraes, Maria Carolina
    Couto, Nuno
    Costa-Silva, Bruno
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2018, 6
  • [55] Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0
  • [56] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
    Moore, Malcolm J.
    Goldstein, David
    Hamm, John
    Figer, Arie
    Hecht, Joel R.
    Gallinger, Steven
    Au, Heather J.
    Murawa, Pawel
    Walde, David
    Wolff, Robert A.
    Campos, Daniel
    Lim, Robert
    Ding, Keyue
    Clark, Gary
    Voskoglou-Nomikos, Theodora
    Ptasynski, Mieke
    Parulekar, Wendy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 1960 - 1966
  • [57] HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers
    Moosavi, Fatemeh
    Giovannetti, Elisa
    Saso, Luciano
    Firuzi, Omidreza
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2019, 56 (08) : 533 - 566
  • [58] Biophysical Techniques for Target Validation and Drug Discovery in Transcription-Targeted Therapy
    Moustaqil, Mehdi
    Gambin, Yann
    Sierecki, Emma
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (07)
  • [59] Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview
    Nagaraju, Ganji Purnachandra
    Farran, Batoul
    Luong, Tha
    El-Rayes, Bassel F.
    [J]. SEMINARS IN CANCER BIOLOGY, 2023, 88 : 67 - 80
  • [60] O'Driscoll L, 2007, ANTICANCER RES, V27, P2115
12345678910